NATCO PHARMA LTD. was incorporated on 19th September 1981in Andhra Pradesh as a Pvt. Ltd. Company as NATCO FINEPHARMACEUTICALS P. LTD. and became a deemed Public Companywith effect from 1st July 1992 under Section 43A of theAct. Subsequently it changed its name to NATCO PHARMALTD. on 18th February 1993 and received change of namecertificate.The Company began operations in 1984 with an objective tomanufacture conventional and Timed Release Dosage forms oflife savings drugs. The company''s factory is located 35km.away from Hyderabad on Bangalore Highway No. 7. It hasfollowing capacities to manufacture a wide range oftablets capsules liquids and dry powders using automatedequipments:-------------------------------------------------- Capacity (Units p.a.) (One shift basis)--------------------------------------------------Tablets 18 CroresCapsulesTimed Release 30 CroresAntibiotics 12 CroresLiquids 1.20 Crore bottles (60 KL)Dry Syrups 0.30 Crore bottlesAerosol 0.24 Crore containers---------------------------------------------------Indigenisation of Microdialysis Cell technology for variousdosage forms was taken up as a challenge and Company hadintroduced Antihistaminic Antianxiety AntiasthmaticCardiac Drugs into Indian Market for the first time insustained action dosage forms. The major productsmanufactured by the company are as follows:FLOCY (CIPROFLOXACIN HCI)NATCOCILLIN (AMPICILLIN)NATAMOX (AMOXYCILLIN)TR PHYLLIN (THEOPHYLLINE)BETACAP TR (PROPRANOLOL HCI)CARDICAP TR (ISOSORBIDE-Dl-NlTRATE)IBUBID TR (IBUPROFEN)NACLO TR (DICLOFENAC SODIUM)CAMRELEASE TR (DIAZEPAM)CEPIAM TR (CHLORPHENIRAMINE MALEATE)POTRELEASE TR (POTASSIUM CHLORIDE)COLDACT (PHENYL PROPANOLAMINE)HCI + CHLORPHENlRAMINE MALEATE)The Company holds the necessary licences issued by the DrugControl Authorities for the manufacture of these drugs atits existing plant at Kothur Mahaboobnagar. The turnoverof the unit increased progressively; the turnover which wasat Rs. 730 lacs for the year 1989-90 has grown to Rs. 3689.24 Lacs for the year 1993-94.The Company has pioneered Timed Release Technology in Indiaby introducing Multi-unit Multi-layered System for thefirst time in India in the year 1985. The company''sformulation Rubinat is ranked second in the Anticancer DrugSegment and first in the Anthracyclines Segment on thebasis of turnover of 1993-94. The Company has been awardedImport Substitution Award (1986) for Timed ReleaseTechnology. It has well equipped Research and Developmentfacilities manned by qualified Scientists. Itsformulations are exported to the CIS States VietnamHongkong China Netherlands Nigeria Tanzania and Kenya.The Annual average exports sales for the last three yearsis 21% of turnover. The Export turnover details for last 3 years are as follows: (Rs. in lakhs)-----------------------------------------------------Year Total Export % to Total Turnover Turnover-----------------------------------------------------1991-92 1169.36 47.39 4%1992-93 2840.00 739.86 26%1993-94 3542.74 1168.64 33%Sept. ''94 3402.59 1740.15 51%(6 months)-----------------------------------------------------The Company is a recipient of WHO Certificate formaintaining good manutacturing practices. The Company isone of the contract manufacturers in the pharmaceuticalsindustry in India and manufactures products for companiesincluding Ranbaxy Laboratories Ltd. Eskayef Ltd. ParkeDavis (I) Ltd. Fulford India Limited Cadila Ltd. JohnWyeth India Ltd. ICI Ltd. and SOL Pharmaceuticals Ltd.
Name | Position |
---|---|
Mr. V C Nannapaneni | Chairman & Ind.Director |
Mr. Rajeev Nannapaneni | Director & CEO |
Mr. P S R K Prasad | Director & Exe. VP (Corp. Engg. Services) |
Dr. D Linga Rao | Director & President (Tech. Affairs) |
Dr. Pavan Ganapati Bhat | Director |